H.C. Wainwright Remains a Buy on Lexicon Pharmaceuticals (LXRX) [Yahoo! Finance]
Lexicon Pharmaceuticals, Inc. (LXRX)
Last lexicon pharmaceuticals, inc. earnings: 4/27 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
lexpharma.com/investors
Company Research
Source: Yahoo! Finance
Wainwright reiterated a Buy rating on Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) with a $6 price target. ?The analyst noted positive post-hoc analyses of sotagliflozin, which showed cardiometabolic benefits such as reduction in HbA1c, body weight, systolic blood pressure, and insulin use. Moreover, the candidate also showed fewer hypoglycemic events after one year in type 1 diabetes patients with normal or mildly reduced kidney function. ?The firm noted that the data aligns with the ongoing STENO1 investigator-initiated trial, which gathers data on diabetic ketoacidosis incidence and could support regulatory decisions. The company plans to resubmit an NDA in 2026 for sotagliflozin as an insulin adjunct in type 1 diabetes. While the firm remains optimistic, he flagged risks such as trial failures, funding shortfalls, or dilutive financing. ?Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) is a biopharmaceutical company focused on the discovery, development, and commercialization of p
Show less
Read more
Impact Snapshot
Event Time:
LXRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LXRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LXRX alerts
High impacting Lexicon Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
LXRX
News
- Lexicon Pharmaceuticals (LXRX) was given a new $6.00 price target by HC Wainwright.MarketBeat
- Lexicon to Present Data on Effect of Kidney Function on the Long-term Efficacy and Safety of Sotagliflozin in Patients with Type 1 Diabetes at 19th International Conference on Advanced Technologies & Treatments for DiabetesGlobeNewswire
- Lexicon Pharmaceuticals (LXRX) had its price target raised by Citigroup Inc. from $2.10 to $2.30. They now have a "buy" rating on the stock.MarketBeat
- Lexicon Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]Yahoo! Finance
- Lexicon Pharmaceuticals (LXRX) had its price target raised by HC Wainwright from $4.00 to $6.00. They now have a "buy" rating on the stock.MarketBeat
LXRX
Earnings
- 3/5/26 - Beat
LXRX
Sec Filings
- 3/16/26 - Form ARS
- 3/16/26 - Form DEFA14A
- 3/16/26 - Form DEF
- LXRX's page on the SEC website